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The purpose of population genomic screening programs is to help in prevention and treatment of 
conditions that takes into account an individual’s unique genetics, environmental, and lifestyle 
factors. Through this “genome-first” approach, individuals at increased lifetime risk for certain 
conditions are identified, allowing them and their relatives to qualify for preventative medical care 
and surveillance (Schwartz et al., 2018). An example institution that utilizes this approach is 
Geisinger’s MyCode Community Initiative, where their goal is to “make healthcare better” through 
research and its application to patient care (MyCode Community Health Initiative, n.d.). MyCode 
reports back medically actionable results for conditions associated with increased risks for 
cardiovascular diseases and developing cancer. One of the hereditary cancer syndromes that 
MyCode reports back to clinical care is Lynch syndrome (LS), a condition with nationally 
recognized guidelines for preventative surveillance measures. MyCode participants with an LS-
associated variant have an interdisciplinary approach to medical care made available to them, 
being offered optional access to methods of facilitating family communication, instituting changes 
to medical management, and considering lifestyle modifications. In this study, 17 MyCode 
participants who received actionable LS results were interviewed to assess potential facilitators 
and barriers affecting family communication, follow-up medical care, and modifying lifestyle. 
Keywords: Lynch syndrome, hereditary cancer syndrome, family communication, medical 
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Lynch syndrome (LS), also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is 
an autosomal dominant condition that presents as a result of inheriting a pathogenic variant in one 
of the five genes involved in the Mismatch Repair (MMR) pathway, MLH1, PMS2, MSH2, MSH6, 
and EPCAM. This syndrome is characterized by an increased risk for biological males and females 
to develop colorectal cancer (CRC) in their lifetime, anywhere from 20%-82% for both sexes with 
a mean age at diagnosis of 44-61 years (Kohlmann & Gruber, 2018; Key Statistics for Colorectal 
Cancer). Endometrial cancer also poses an increased risk for biological females, up to a 46% 
chance for developing this cancer type in their lifetime, along with elevated risks to develop 
ovarian cancer (Kohlmann & Gruber, 2018). There is also an increased risk for both sexes to be 
diagnosed with cancers of the biliary tract, brain (esp. glioblastomas), pancreas, prostate, skin (esp. 
sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), small bowel, stomach, and 
urinary tract (Kohlmann & Gruber, 2018). The wide variability in risk percentages and uncertainty 
surrounding the development of LS-related cancers is due to the fact that each gene involved in 
the MMR pathway is associated with different risks for the variety of cancer types, in addition to 
the influence of other contributing genetic and environmental factors (Kohlmann & Gruber, 2018). 
An individual who has been diagnosed with LS should be provided with a comprehensive 
overview of the management process in order to understand how to appropriately attend to their 
care moving forward. 
Upon receiving an LS-associated variant, patients are faced with a multitude of decisions 
pertaining to medical management, lifestyle modifications, and whether or not they would like to 
communicate their genetic information with their family members. Medical management 
recommendations revolve around the consideration of preventative surveillance measures, such as 
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scheduling annual/biannual colonoscopies, upper endoscopies every 3-5 years, and annual 
dermatologic exams (Lynch syndrome, 2019). The benefit of increased surveillance can be 
exemplified by colonoscopies, which have been found to play a role in identifying cancers early 
and preventing colorectal cancer altogether by removing certain types of polyps, thereby extending 
the lifespan (Grover & Syngal, 2010). Prophylactic surgery options are also given to females as 
options, such as obtaining a hysterectomy and/or risk-reducing salpingo oophorectomy (RRSO), 
once childbearing is complete. Recommendations for maintaining a healthy lifestyle involve 
keeping up with a diet that is high in fruits and vegetables and low in red meat, little to no alcohol 
consumption, a dedication to exercise and maintaining a healthy weight, and a cessation of 
smoking (Burton et al., 2010). When an individual is identified to have an LS variant, that 
information is important for their relatives' health care given that LS is inherited in an autosomal 
dominant manner (Kohlmann & Gruber, 2018).  
“Genome-first” clinical encounters, or those where patients present to care based on a genomic 
finding, preceding any manifestations of features, are increasing as a result in the uptake of 
genomic sequencing (Schwartz et al., 2018). Whether it be for research or for clinical utility, there 
has been a decrease in cost and an increase in the ability to analyze genomic databases for 
medically-actionable variants (Schwartz et al., 2018). Programs such as these are able to identify 
patients who are at higher risks to develop a phenotype on a genomic level, allowing them to 
present to care for increased surveillance, medical treatment, and additional preventative measures 
that are targeted to their condition prior to experiencing symptoms (Schwartz et al., 2018). 
Geisinger’s MyCode Community Health Initiative, which has a goal to “make healthcare better” 
through research and the application of that research to patient care, is an example of an 
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opportunistic genome screening program that provides such “genome-first” care (MyCode 
Community Health Initiative, n. d.).  
MyCode returns actionable genetic results to clinical care if participants are identified to carry a 
pathogenic/likely pathogenic variant in one of twenty-five conditions, including LS (Frequently 
asked questions, n. d.). As of February 1, 2020, a total of 1,489 participants have received results, 
of which 175 of them are LS-related (MyCode Community Health Initiative, n. d.).  Results are 
disclosed over the phone by a genetic counselor. Participants are offered a follow up genetic 
counseling visit for education and psychological support. Participants with results also receive a 
summary letter with details about LS cancer risks and management recommendations, a copy of 
their genetic test report, and a “Dear Family” letter or online family sharing tool to aid in sharing 
the results with at-risk relatives. The result is uploaded to their Electronic Medical Record (EMR) 
and their primary care provider is notified. Geisinger’s Inherited Risk Gastrointestinal (IRGI) 
clinic is a multidisciplinary clinic where a variety of specialists are available to educate and 
coordinate care related to LS surveillance and prevention options. In this study, we interviewed 
MyCode participants identified to have an LS-associated variant about how receiving a positive 
genetic test result impacts how they have been communicating the information with their at-risk 
relatives, following medical management recommendations, and implementing lifestyle 
modifications.  
Methodology 
Study Population and Data Collection: 
This qualitative study conducted in-depth, semi-structured phone interviews with participants from 
MyCode, who had been found to have an LS-associated variant (Creswell, 2007). We gathered the 
personal responses of these participants regarding their experiences in sharing the genetic 
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information with at-risk relatives and following recommended medical guidelines and lifestyle 
modifications. We utilized Geisinger’s MyCode program records containing 126 individuals who 
were identified to have LS. From MyCode’s contact directory, we recruited participants who were 
18 years of age or older to request their participation, obtained their consent to participate, and 
scheduled the telephone interview date and time. The interview questions focused on eliciting 
patient experiences with communicating their MyCode genetic test result to their family members, 
how they have navigated associated medical management recommendations, and what lifestyle 
modifications they have pursued. Examples of interview questions for each domain are as follows 
in Figure 1. 
Figure 1: Examples of Semi-Structured Interview Protocol Questions for Primary Domains 
Family Communication 
How did you choose to communicate this genetic information with them? 
Tell me what is preventing you from sharing it with your family? 
What support do you think would help you share this with family? 
Medical Management 
What have you been doing differently regarding your healthcare choices, if anything, since 
receiving your MyCode results? 
What, if any, issues did you have in getting insurance to cover your care related to Lynch 
syndrome? 
 9 
Describe what your experience has been like staying on top of these healthcare choices during 
the COVID-19 pandemic? 
Lifestyle Modifications 
What recommendations have you been told or seen? 
What recommendations have you followed, if any? 
How did other sources, if any, influence your past choices regarding the recommendations 
proposed to you? 
 
Interviews were conducted between December 2020 and January 2021. A consent statement was 
read before beginning the interview to obtain participant’s consent to audio recording the 
interview. The interview questions elicited personal responses from the participants regarding their 
experiences pertaining to their LS-associated variant disclosure. Each interview lasted for 30 to 45 
minutes, were de-identified upon completion, and were sent for transcription. Once data collection 
was completed, participants were thanked for their participation in the form of a $20 Amazon gift 
card. 
Data Analysis: 
Interviews were coded iteratively in levels using ATLASti.8 software. First, we engaged in open-
coding to identify initial themes amongst participant responses that began to answer the project’s 
research questions. Emergent themes from open-coding were broadly classified into facilitators 
and barriers of participant’s actions related to family communication and health care management. 
Using Owen’s thematic interpretation criteria (1984) as a guide, we were able to identify key 
themes to further categorize our interview data. Our second-level coding process was characterized 
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by naming specific facilitators and barriers for (a) family communication about LS results, (b) 
lifestyle modifications related to LS, and (c) medical management to reduce cancer risks related 
to LS. These facilitators and barriers were captured in a table with exemplar quotes and reviewed 
by the study team. Through this table, we compiled the code book that was acknowledged 
throughout the data analysis process. To initiate the third-level coding process, an axial coding 
protocol was followed and the open codes were related to one another via an established code 
name and meaning of the code (Saldana, 2013). Finally, we refined and expanded on themes and 
subthemes within each of the three domains to identify connections among facilitators and barriers 
related to communication and health outcomes. Exemplar quotes are included below to provide a 
thick description of each theme of facilitators and barriers within each of the three domains.  
 Results  
Seventeen phone interviews were completed with 8 male and 9 female participants (see Figure 2 
for participant age distribution). After qualitative analysis of these interviews, three overarching 
themes emerged: [1] communicating genetic risk information to family members, [2] changes in 
medical management, and [3] changes in lifestyle modifications. Each major theme included both 
facilitators and barriers that influenced participants’ action regarding family communication, 
changes to their medical management, and implementation of particular lifestyle modifications. 
Figure 2: Participants Characteristics (N = 17 individuals)  
Age  30-50 (N = 4) 
51-70 (N = 8) 
71-90 (N = 5) 
Sex Female (N = 9) 
Male (N = 8) 
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Pathogenic/Likely 
Pathogenic Gene Variants 
MLH1 (N = 3) 
MSH2 (N = 2) 
MSH6 (N = 7) 
PMS2 (N = 5) 
 
 
Communicating genetic information with family members 
All participants reported that sharing this information with their relatives was crucial. Participants 
elaborated on who they chose to communicate information about their genetic test result with in 
their family, highlighting common barriers and facilitators of sharing the genetic information. 
Facilitators 
Participant perceptions of their duty to share results with family. All participants said they valued 
how important these genetic test results were to share with their immediate family members. They 
described how their concern for increased risk for LS-related cancers and the qualification for 
increased surveillance options motivated their sharing behaviors with at-risk relatives. Exemplary 
quotes from two participants are as follows:  
“I felt, like, some obligation to do it I guess, some concern for them, that if this could help 
protect them, help to detect a problem early. I wanted them to have that information 
available to them. I wanted them to be able to have that same level of care that I have.” 
“That was frustrating because as a mother you want your children to be healthy. The only 
things I really, really want for my children is to be happy and healthy. And I could say 
sometimes there are a lot of things you can't control with happiness, but the healthy part 
that as well, there are some things you can kind of try to be proactive about is your health, 
so I presented this information that I had with my children…” 
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Being a parent and the feelings surrounding raising children was found to be a large component of 
why participants chose to share their genetic results with their children. Feelings of concern, 
wanting the best in terms of healthcare, and the desire for their children to live a happy and healthy 
life dominated their reported reasons to communicate LS variant information with their children. 
It was also observed that children who received this information first felt obligated to share this 
information with their parents. Moreover, the availability of preventative surveillance measures to 
reduce the risks for LS-related cancers influenced participants who received a LS-associated 
variant to share the genetic information with at-risk relatives.  
Methods of communicating with family. Many participants utilized phone calls as a method to 
initiate sharing news of their genetic test result, especially when family members did not live 
within close proximity to them:   
“On the phone call because they live overseas. I had to get it from Geisinger, a genetic 
letter, but I didn't want to send it over there, so I made a phone call.” 
As is exemplified in the previous quote, a phone call often opened the line of communication 
between family members prior to the patient letter. However, there were some instances in which 
only a phone call was described as the most practical way to share the information with relatives, 
such as when participants reported to have large families: 
“I just talked to them on the phone. I have a huge family, anyway, I can’t go and visit 
everybody, you know some of my closest uncles and stuff or my cousins yeah I’ll tell them 
in person or whatever you know if we chose to talk about it.” 
In addition to phone calls, participants often discussed using the “Dear Family” letters provided 
by Geisinger to communicate the genetic information with their at-risk relatives.  
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“Well, initially I just kind of told them verbally, and then Geisinger sent me a packet that 
I could share with the kids. I made copies for my 4 kids and my sister...”  
Barriers  
Lack of contact or closeness. Despite the participants’ perception of the importance of the result 
implication, they said one of the roadblocks to communicate the genetic information was the lack 
of contact or closeness to their family members, exemplified as follows: 
“We don’t talk, but I did send the information [patient letter] to my nephew… Hopefully 
my brother will get the information...I haven't verbally talked to anybody because they 
don't talk to me…”  
“I actually have 3 half siblings in the United States and I don't really talk to them much…” 
Young age. Participants reported a reluctance to disclose information regarding the LS-related risks 
associated with the genetic test result to relatives who are under the age of 18. However, some 
participants stated that they are planning to share this information with their family members as 
they get older and can make decisions pertaining to genetic screening and reproductive options: 
“My oldest is 15, she kind of knows to a point. I mean she knows I have Lynch syndrome 
and she kind of knows what it entails but she doesn't know everything. We haven’t exactly 
sat down to explain everything to her.” 
“They're [grandchildren] too young. If I'm still around...when they get old enough, I'll tell 
them myself.” 
Changes in Medical Management 
Obtaining medical management and surveillance recommendations are one of the benefits of 
knowing about hereditary cancer risk. Most participants described being able to follow the medical 
recommendations related to LS as a result of several factors that facilitated their medical 
 14 
management changes. Some participants also expressed experiencing several barriers to receiving 
and/or implementing suggested medical care. 
Facilitators 
Access to and coverage by insurance. Participants said their ability to follow medical management 
and surveillance recommendations was facilitated by their insurance accessibility and coverage: 
“I don't have any financial burden from that. It is all insurance covered.” 
A majority of participants provided positive feedback in regards to getting their health insurance 
plans to cover their care related to LS. A frequent comment participants made was that there had 
been issues obtaining health insurance coverage for other medical issues not related to LS, and that 
coverage related to their LS-related cancer prevention remained unaffected.  
Institutional Coordination of Care. Participants in this study reported a value having access to the 
IRGI clinic, or “Lynch clinic” as the participants referred to it, offered by Geisinger and outlined 
the care that they received: 
“I would say that the Lynch clinic is really nice because everything is all there, rolled up 
into one ball there. I can get scheduled and have my urology appointment, my urinalysis, 
my colonoscopy, my vaginal exam, everything always in one day, as opposed to having it 
here, there, and everywhere.” 
“I have never had an appointment in my life where you got the care that you did and 
everybody, it was like a one-stop shop, you go to the doctor appointment and everybody 
comes to you...I never experienced that before…”  
Moreover, the role that Geisinger genetic counseling assistants (GCAs) play in contacting 
individuals with an LS-associated variant who are due for their surveillance appointments was 
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described by participants as facilitating their adherence to an appropriate medical management 
plan.  
“Positive thing is the fact that Geisinger does have kind of a dedicated resource 
coordinator and one part of that is setting up those workshops, for instance, but also to 
follow up and follow through by that coordinator office as opposed to having to kind of 
drive these things on my own or with my primary care physician. I think that's made this 
easier. So, that was a plus.”  
Healthcare professionals (HCPs) advocating for their patients. In some cases, participants 
described healthcare providers providing excellent patient-centered care and advocating on behalf 
of the participant and their at-risk family members. Of important note, this advocacy was highly 
valued when participants were attempting to seek cascade testing for their immediate family 
members, such as their children. While not a common occurrence among participants, access to 
familial genetic testing was facilitated by the efforts of medical professionals already involved in 
the patient’s care: 
“Now that I'm thinking about it, he [oncologist] gave me a genetics test too on his own 
because then he pushed for my daughters to have it because he didn't want to give my 
children it. And he had to fight tooth and nails for my girls to get it.” 
Participants elaborated on the active role their Genetic Counselors played in advocating on their 
behalf to receive appropriate care set by the NCCN established guidelines pertaining to LS. In 
certain cases, participants were very well aware of the care they should be receiving, such as being 
scheduled for more frequent colonoscopies than those in the general population. However, they 
stated that they turned to their Genetic Counselor for validation, especially if they were being told 
conflicting information otherwise. 
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“I went to my genetic counselor this year, and said he [GI] is going to see me in 3 years, 
they [genetic counselor] were right on it, these people help you, they advocate for you, and 
that we’re going to refer you to somebody else because it is not right.” 
Close relationship with physicians. Many participants highlighted how having a close relationship 
with their physicians helped them feel comfortable, confident, and supported throughout their 
medical journeys. A majority of participants recognized the strong presence their primary care 
physician (PCP) played in discussing and coordinating their care, especially pertaining to LS. The 
willingness of the PCP’s to have an open dialogue with their patients was described by participants 
as leading them to a renewed sense of self-motivation and validation attempting to better manage 
their risk for LS-related cancers. 
“It's something that in my kind of normal periodic checkups he will bring that up and we'll 
talk about the preventative action and surveillance as he is reviewing my medical 
record.  He asks if I have any questions or if I need any referrals or if I have any 
concerns.  So, I think that, in my case I am very satisfied with my primary care's actions 
on this……. It gives me some confidence, I guess.  It reinforces what I'm doing.  He seems 
to agree with everything I'm doing and doesn't have anything else to suggest.  So, I am 
feeling satisfaction there I guess.” 
Support person. Some participants stated that getting the support of a family member helped to 
encourage them in multiple aspects of their care related to LS, from ensuring they attend healthcare 
appointments to contacting health insurance companies when necessary. 
“...my oldest daughter will say "Mom, I think it's time." You know? Each year, I don't miss 
anything, my mammograms, my colonoscopies, none of it. I make sure my daughter doesn't 
miss hers.”  
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“He [husband] was very supportive. He did anything that needed to be done. He would 
help me do anything that needed to be done... He has kept me on top of talking to the 
insurance company because he can't do that for me, and he has taken me to my 
appointments.”       
Participant’s perception of their HCPs educational efforts. Participants stressed the importance of 
feeling like their HCPs were up-to-date on LS and the risks associated with their particular genetic 
difference. 
“A genetic counselor/oncology team... see me together once a year to to follow up, see how 
I am doing, giving me new updates about Lynch Syndrome and my genetic defect variant, 
and what is new about it and all that stuff, if anything changed on what I should be doing.” 
Barriers 
Alternative chief complaint. Participants with alternative medical chief complaints, whether they 
have been lifelong or a more recent diagnosis, tended to not prioritize LS-related care. Lifelong 
medical concerns included conditions such as irritable bowel syndrome or Crohn’s disease, and 
recent diagnoses were often of cancers unassociated with LS, such as hematologic in nature. 
Participants emphasized that medical professionals involved in their care often did not address LS 
when there were other medical issues at hand.  
“......My doctor and I usually have something much more active going on to talk about.”  
“Not doing much pertaining to Lynch syndrome at all. I was just dealing with just starting 
[multiple myeloma] cancer protocol.” 
Another priority participants described was being a caregiver for a family member. Participants 
did not prioritize their own medical care if they had a family member affected by a life-threatening 
medical condition who required consistent healthcare assistance.  
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“I did my best to keep up…I shouldn't use this as an excuse, …. but the truth is that when 
you're taking care of somebody else and you are the caregiver, it is hard to think about 
yourself when you are thinking about that other person all the time...you are like the last 
person on the list.” 
COVID-19 implications. The COVID-19 pandemic has had a huge impact on several aspects of 
healthcare in the year 2020, especially when it came to whether or not hospital systems continued 
to offer elective procedures such as colonoscopies, that LS patients rely on receiving on a 
consistent basis. In a few interviews, some of the participants had complaints about surveillance 
appointments related to LS having been postponed due to the pandemic, as their surveillance 
schedule happened to fall during months in which the United States was experiencing country-
wide shutdowns to many public establishments, including hospitals and high-risk surveillance 
centers.  
“No challenges other than an appointment being delayed because the hospital was 
choosing to avoid elective or non-critical procedures, so that resulted in a couple month 
shift in that particular session.” 
HCP’s limited knowledge about LS. Several participants mentioned that they were facing HCPs 
with limited or conflicting knowledge about LS and their management plan. As a result, 
participants were confused regarding their management and surveillance plans moving forward. 
“At first they said you need to get a hysterectomy and then I didn’t need a hysterectomy 
like a radical hysterectomy. I have to wait until I am at least 40 some... Some of them had 
different opinions than others...it seems like not everybody was on the same page with, like, 
as to what they were telling me.” 
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In addition, participants stated that they were surprised by the lack of comprehensive knowledge 
their HCPs had about LS. Furthermore, participants stressed that some medical professionals they 
saw on an annual basis would address cancer risk and cancer prevention relative to their own 
specialty, but would not address LS-related cancers specifically. The following participant quote 
addresses both sides of this sub-theme that we heard in our interviews: 
“...that kinda surprised me. They kinda were fishing for me to give them information 
instead of them giving me information. It was very weird. It's like they knew what it was, 
but they still at the same time wanted some kind of more clarification or something about 
it…..Like my gynecologist. They were more like straight shooting on cancer, but not 
specific Lynch syndrome….” 
Lifestyle modifications 
Along with medical management changes, participants discussed lifestyle modifications after 
being informed of their LS-associated variant as part of their preventative care. They considered 
making these changes after hearing their doctors discuss these options, reading about them online, 
or receiving advice from individuals in their communities. 
Facilitators  
Lifestyle modification communicated. Participants mentioned that they implemented some 
modifications in their lifestyle, such as following a healthy diet, avoiding red and processed meats, 
and/or consuming certain supplements. They said those lifestyle modifications were usually 
communicated and recommended by their HCPs as part of their healthcare plan. 
“Precautions-wise, I guess as a family, we are trying to avoid cured meats is the one I 
think comes to mind first, things that are nitrates, salami, bacon and those sorts of 
things...”  
 20 
“...but then he also gave me something, turmeric, which I do believe helped me a lot to 
fight the cancer. He has me on a daily fiber pill and vitamin C, immune system, immune 
medicine....and I truly believe it [turmeric] helped.”  
Overall, participants reported that they adopted behaviors that promoted a healthy lifestyle into 
their daily regimen. This included exercising and being cognizant of managing their weight 
appropriately. Participants who attended Geisinger’s IRGI clinic further elaborated on the lifestyle 
modifications they decided to make, such as specializing their diet to include organically-grown 
products. 
“I'm primarily, it’s just with diet and weight, exercise,....”  
“...the one doctor I saw through the Lynch clinic had really suggested a lot more organic 
foods, so we switched to a lot more organic.” 
Barriers  
Lifestyle modifications not communicated. Although some participants stated that they made some 
modifications in their lifestyle after learning of their LS-associated variant, many of them had not. 
If participants disclosed that they did not implement any lifestyle modifications, a majority were 
prompted to share if they have been told about potential lifestyle modifications to consider or not. 
A common response participants had was, “I haven't really been told anything”. Therefore, 
participants reported not implementing any lifestyle modification because of a lack of 
communication about what lifestyle modification they could follow as part of their preventative 
care for LS-related risks. 
Discussion 
The focus of this study was to investigate how individuals identified to have LS-related cancer 
risks through MyCode population genomic screening communicate the genetic information with 
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their family members, follow medical recommendations, and lifestyle considerations. Results of 
this study identify the facilitators and barriers to family communication behaviors, following 
medical recommendations, as well as lifestyle modifications after receiving an LS-associated 
variant result. 
Family communication about genetic information and risks is crucial to at-risk relatives to utilize 
the best possible genetic healthcare services. Patients with a hereditary cancer syndrome diagnosis 
feel responsible for sharing the genetic test result with at-risk relatives (Chivers-Seymour et al., 
2010). Providing patient letters has been a common way for HCPs to facilitate family 
communication to ensure that genetic information is communicated accurately to initiate making 
an informed decision about whether to pursue a genetic test or not (Mendes et al. 2016). The 
availability of patient letters has increased the pressure that patients felt to communicate the genetic 
information with at-risk relatives; however, using a patient letter to share the risk with relatives 
increased patients’ confidence, further helping them to fulfill their sense of duty to share (Dheensa, 
Lucassen, & Fenwick, 2018). Our results showed that Geisinger’s equivalent to a patient letter, the 
“Dear Family” letter, was utilized to facilitate family communication frequently; however, it was 
often referenced or distributed to at-risk relatives after communication was first initiated through 
a personal phone call. Participants found that the letter was useful for their own benefit and allowed 
them to fulfill a sense of duty to alert their family members to the potential risk of having an LS-
related variant.  
Coordination of care was reported by participants to be one of the facilitators of following medical 
management guidelines for their LS-associated variant. Studies have shown that having a genetic 
work-up, including genetic testing and genetic counseling, has shown an increase in the uptake of 
recommended cancer surveillance (Stoffel et al., 2010). Per MyCode Community Health Initiative 
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working protocol, MyCode participants are to be contacted by a member of the “clinical genomics 
team”, which involves clinical geneticists, licensed genetic counselor, genetic counseling 
assistants, and other genetics healthcare professionals, disclosing pathogenic/likely pathogenic 
genetic results to them prior to seeing medical providers who will be managing their care moving 
forward (Williams et al., 2018). For participants who were identified to have an LS-associated 
variant via MyCode, incorporating the step of speaking with the clinical genomics team to facilitate 
a genetics evaluation and a follow-up plan simulates what has been found to be successful in other 
studies examining coordination of care moving forward. Assisting in appropriate follow-up 
management rather than simply learning of their genetic test result was a vital piece to inform them 
of the importance of consulting with appropriate specialists and pursuing preventative surveillance 
for LS-related cancers (Stoffel et al., 2010). The coordination of follow-up care on behalf of the 
MyCode team provides participants who receive a pathogenic/likely pathogenic with an 
established medical care team partnership, providing guidance in managing the increased risk for 
LS-related cancers. 
Aspects of a healthy lifestyle are known to reduce the risk of the onset of colorectal cancer for 
survivors and previvors, but less information is known about the direct effect these lifestyle 
modifications have on the LS-associated cancers specifically (Burton, et al., 2010). Considering 
there is little research currently surrounding the effectiveness of these recommendations, there is 
still debate regarding how crucial it is for different medical providers to report on the utility of the 
changes, and who should assume this responsibility (Burton, et al., 2010). It has been proposed 
that the environment in which instructing, information-tailoring, and discussion about patient 
behavior was expected, such as a genetic counseling session, would be ideal to review aspects of 
how and which lifestyle modifications to incorporate (Burton, et al., 2010). Some participants 
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shared that they found utility in discussing potential adjustments that can be made to one’s lifestyle 
to be empowering due to the level of control they have in maintaining a healthy lifestyle, such as 
by what they choose to consume and how they choose to manage weight. Without having 
established lifestyle modification recommendations as there are with medical management 
recommendations, proposed lifestyle modifications are entirely up to the individuals with LS to 
incorporate what is best for them. This seems to provide these individuals a sense of control in an 
otherwise uncertain scenario with the potential risk to develop an LS-associated cancer.   
  
Conclusion  
Practice Implications  
This study identified major themes related to facilitators and barriers of communicating LS genetic 
test results to their family, and using those results to guide their personal medical management, 
and lifestyle modifications. This study provides a unique perspective as it assesses what 
participants were willing and able to share with other family members and incorporate surveillance 
protocols and lifestyle modifications into their preventative health care.  
Receiving LS-associated variant information indicates individuals’ increased risk for certain 
cancers and necessitates the consideration of additional medical care to detect and prevent these 
cancers. This information can increase anxiety and uncertainty for individuals with LS. Negative 
emotions and risks can be aggravated by healthcare barriers including lack of care coordination, 
limited HCPs knowledge, and absence of patient-centered communication (Campbell-Salome et 
al., 2020; Schneider et al., 2018). Patients with LS may face many challenges to regularly follow 
the frequent and complex (ex. colonoscopy preparation) surveillance procedures. For participants 
in the current study, these potential barriers were largely overcome by institutional coordination 
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of care and HCPs support, highlighting these as critical facilitators for participants to follow 
recommended medical management. 
The utility of how an interdisciplinary approach can be used to coordinate cancer patient care was 
a shared sentiment among the participants who took part in Geisinger’s IRGI clinics (Tremblay et. 
al, 2017). This care model benefits patients by providing a comprehensive approach to 
coordination of preventative care. Furthermore, potential barriers to care are eliminated by 
ensuring the medical care team is on the same page when it comes to personalized patient care 
related to LS recommendations. Receiving care annually through the IRGI clinic facilitates 
successful long term follow up and provides an example of how a healthcare organization can 
support continued communication with patients identified to have hereditary risk. The 
coordination of the IRGI clinic is also supported by both GCs and GCAs. With the role of the GCA 
constantly expanding (Hallquist et al., 2020), other healthcare systems could consider the model 
of GCA support for care coordination for individuals with hereditary cancer risk syndromes.  
With the continued advancements in genetic testing technology, there is beginning to be a shift in 
the medical field from the “screen first, genetic/genomic testing second” method to now starting 
with genetic/genomic testing to identify individuals who are at a higher risk to develop additional 
cancer diagnoses in order to personalize recommended surveillance protocol to best personalize 
their care (Schwartz et al., 2018). Moreover, internal research genomic profiling of tumors at high-
volume cancer centers is increasing as we continue to try to learn more about the onset of cancer 
(Cheng et al., 2015). In addition, clinical diagnostic laboratories are creating diagnostic testing 
platforms to differentiate sporadic cancers from those that were caused by having a LS-associated 
pathogenic/likely pathogenic variant (Gray et al., 2018). As hereditary cancer risk is increasingly 
identified in unselected populations, it is imperative that those individuals be supported in pursuing 
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appropriate medical care and discussing the results with family members. A major theme that 
emerged during our analysis was that participants benefited from supportive information about the 
result and care coordination. This facilitated the spoken uptake in surveillance and willingness to 
share with family members amongst the participant group. 
Limitations 
A limitation of our research is that the data we collected was from 17 participant interviews who 
were chosen from a group of 128 total individuals stratified by biological sex, age, and the 
particular gene in which they received a pathogenic or likely pathogenic result in through the 
MyCode Community Initiative. As a result of this small sample size, we are unable to conclude if 
these feelings and impressions are shared amongst a larger cohort within this particular subset of 
individuals. To add, this study focused on the population screening scaffold of one major medical 
center in the United States, Geisinger. Many of the components that participants mentioned are 
specific to being involved in the Geisinger system, such as insurance plans, access to LS-specific 
clinic environments, and an integrated genomic research center that can connect them to the 
appropriate resources for better facilitation of their preventative management. 
Reliance on patient stories and their recollection of past medical care initiatives, known family 
action steps regarding surveillance and pursuing genetic testing, and how past conversations went 
with family members when relaying the genetic test result were also a limitation of our study. 
Considering it may have been anywhere between 1-3 years since the results were disclosed, time 
may have influenced the amount of information participants shared during the interview. 
The conversations with their family also more than likely occurred closer to the time of result 
disclosure, allowing for time and family member reaction to influence what they remember and 
disclosed during their interview. 
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Future Directions 
A potential future direction for this project would be to expand this study in a quantitative fashion, 
measuring what facilitators and barriers exist within this patient population. Thereafter, contacting 
more individuals from the MyCode patient database who received an actionable LS result or by 
contacting other large-scale medical centers across the United States who have similar population 
screening/surveillance protocols in place would allow for a more diverse data set regarding topics 
such as feasibility to maintain medical and lifestyle modification recommendations, the role 
insurance has played in their coverage of care, and compliance with advice from healthcare 
professionals. Also, a larger cohort of participants would provide for more patient experience 
stories, potentially expanding the scope of our current study to address more aspects of the 
healthcare system involved in preventative cancer surveillance. Considering that MyCode 
continues to return results to participants during the COVID-19 pandemic, it could be important 
to consider experiences of individuals more recently notified of an LS result. This would allow us 
to learn more about their experience regarding following through with preventative healthcare 
measures, having access to medical management resources, and communicating with their family 
members while adhering to strict social distancing requirements. This would involve participants 
having to make choices about coming into contact with HCPs in a hospital setting while trying to 
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Interview Questions Guide  
Hello, my name is [Brooke/Reem] and I am a genetic counseling graduate student at Sarah 
Lawrence College. Thank you again for agreeing to participate in this study. Is now still a good 
time for our call?  
As a reminder, your participation in this is voluntary. I expect that this interview will take between 
45 minutes-1 hour and it will be voice recorded. I will not record your name and your information 
will remain confidential. Please be honest with your responses. You can say whatever you want-
nothing will hurt my feelings and nothing you say will impact your care at Geisinger. You may 
choose to skip any question, just let me know you’d like to not answer it. I appreciate your 
willingness to help with my project. To thank you for your time, we’d like to send you a gift card 
via email. Can you please confirm that your email address is XXXXX? 
Do you have any questions for me before we begin? 
Is it okay if I start recording now? 
Broad Question Probe(s) Main idea(s) 
Thinking back to the 
first time you received 
your MyCode result 
pertaining to Lynch 
syndrome, what were 
your initial thoughts? 
Probe-How have you been feeling 
since? 
 
Probe-What concerns have you had? 
Document the patient’s 
initial thoughts and 
feelings about their result 
to be used as a baseline 
for how they’ve changed 
over time. 
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Tell me what you knew 
about Lynch syndrome 
prior to receiving your 
MyCode result?  
 
Probe-What have you learned about 
Lynch syndrome after receiving your 
MyCode result? 
 




Lynch syndrome before 
and after receiving their 
result. 
 
Identify the information 
source(s) and how patient 
knowledge of the 
condition has changed 
over time. 
What have you been 
doing differently 
regarding your 
healthcare choices, if 
anything, since 
receiving your MyCode 
results? 
1) Probe-What did you learn from your 
doctor(s) and/or elsewhere? 
a. What recommendations have you 
been told or seen? 
b. What recommendations have you 
followed, if any? 
I. Tell me about your 
experience in keeping up 
with these 
recommendations? 
Document how patients 
are incorporating medical 
and lifestyle 
recommendations in their 
healthcare management. 
 
Assess how the COVID-
19 pandemic affected 
patient experience in 
regard to healthcare 
choices. 
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II. Tell me about what 






been like staying 





2) Probe-How did other sources, if any, 
influence your past choices regarding 
the recommendations proposed to you? 
a. Who/What did influence them? 
b. What made you decide that that 















What has been easy or 
straightforward about 
managing the risk for 
 
Assess what has come 
easily for the patients in 
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Lynch syndrome-
related cancers (e.g. 
colorectal and small 




managing their cancer 
risk.  
While attempting to 
receive care for Lynch 
syndrome, what, if 
anything, was difficult 
for you before the 
COVID-19 pandemic? 
 
1) Probe-What, if any, issues did you 
have in getting insurance to cover your 
care related to Lynch syndrome?  
 
2) Probe-What, if any, problems did 
you have in talking to your doctor about 
Lynch syndrome?  
a. Can you describe this experience 
and how it made you feel?  
 
3) Probe-What, if any, problems did 
you have in seeing a doctor (e.g. 
appointment availability, proximity of 
specialty clinics, etc.)? 
 
Determine multiple 
barriers patients could 
have experienced in 
seeking appropriate 
healthcare prior to the 
limitations encountered 
during the COVID-19 
pandemic. 
 
Determine how patients 
tried to overcome these 
barriers. 
 
Research what patients 
believe should be 
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4) Probe-In thinking about these issues, 
how did you try to get your appropriate 
care? 
 
5) Probe-What do you think is needed 
to change in order for you to have 
received appropriate care? 
 
adjusted in order to 
prevent these barriers 
from limiting their access 
to appropriate care. 
Have you spoken with 
your family members 
about your diagnosis? 
 
1) Probe (If yes)-Who in your family 
did you share this information with? 
a. How did you choose to 
communicate this genetic 
information with them? 
b. Can you describe how they 
responded? 
I. What about their reaction 
surprised you, if 
anything? 
II. Who, if anyone, sought 
out medical services? 
Specifically, genetic 
testing? 
Identify how genetic 
information is being 
communicated and 
received within the 
patient’s family and with 
whom (1st/2nd degree 
relatives). 
 
Determine who in 
the  patient’s family 
decided to seek medical 
services and their process 
in doing so. 
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1. What has been the 
outcome of this 
relative doing 
this, pertaining to 
their medical 
care? (e.g. health 
choices, 
diagnosis, etc.) 
2. What has been the 
outcome of this 
relative doing 





c. How did you feel sharing that 
information with them?   
2) Probe (If no)-Tell me what is 
preventing you from sharing it with your 
family? 
a. How does that make you feel? 
Identify the healthcare 
and emotional outcomes 
that resulted from the 
family member(s) 
seeking medical care and 
how the patient feels 
about their decision to 
share. 
 
Identify the barriers that 
are interfering with the 
patient’s comfortability 
for communicating the 
genetic information 
within their family and 
what support they would 
need to do so.  
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b. What support do you think 
would help you share this with 
family? 
 
